news-events HTG & Oncologie biomarker development
masthead-news

News & Events

HTG Molecular Diagnostics and Oncologie, Inc. Complete Master Agreement to Partner on Biomarker Development for Immuno-oncology Drug Development

TUCSON, Ariz., Aug. 03, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications and Oncologie, Inc. an innovative biotechnology company with operations in Boston and Shanghai, today announced the completion of a master agreement where the companies have agreed to partner on the development of biomarkers associated with Oncologie’s Immuno-oncology pipeline.

Read more 

Posted on:

Return To List

Page last updated August 03, 2018